Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Evaluable Disease

Known as: Evaluable 
Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BACKGROUND Paediatric low-grade glioma is the most common CNS tumour of childhood. Although overall survival is good, disease… Expand
Review
2019
Review
2019
BACKGROUND A solitary fibrous tumour is a rare soft-tissue tumour with three clinicopathological variants: typical, malignant… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Review
2019
Review
2019
Abstract Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Review
2019
Review
2019
INTRODUCTION Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging… Expand
Review
2019
Review
2019
  • C. White
  • Journal of clinical pharmacology
  • 2019
  • Corpus ID: 73452711
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are… Expand
Review
2018
Review
2018
This article summarizes key review findings that supported the approval of tocilizumab for treatment of severe or life… Expand
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
Importance Measurement-based care (MBC) is the systematic evaluation of patient symptoms before or during an encounter to inform… Expand
  • table 1
  • table 3
Review
2018
Review
2018
Importance Effective treatment options are limited for patients with advanced, metastatic esophageal cancer progressing after 2… Expand
  • table 2
  • table 1
  • figure 1
  • table 1
  • table 2
Review
2018
Review
2018
Background MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2